How did we get here? Where are we going? What now? These are the thoughts crossing many policymakers minds as we approach the six month benchmark of health reform being enacted into law. When legislation was passed, some thought the debate was over. We know that it is just beginning. States and the federal government must focus on implementing the litany of provisions outlined in the legislation. Congress will likely have to revisit legislation to make refinements or technical corrections. Oh, and let’s not forget about the politics surrounding this new law.
Many states are taking measures to meet with thought leaders, manufacturers, payers, and providers to determine how to best implement healthcare reform legislation in their state. On Friday, Indiana Life Sciences hosted a day long discussion entitled, “Healthcare Reform: The Road Ahead”. Leaders from across the healthcare community gathered to discuss healthcare reform implementation in Indiana. Lilly’s own Jay Bonitt, Vice President of Federal Affairs, participated in the discussion to provide our perspective on these important issues. The discussion in Indiana was very similar to ones happening across the country. States are grappling with key issues that must be resolved during implementation.
Some of the issues on the top of our list include: (and I apologize for throwing in some acronyms but sometimes it cannot be helped when you live and work in Washington, D.C.) IPAB, Comparative Effectiveness Research (CER), and a pathway for biosimilars.
Later this week, we'll answer the burning question on everyone's mind: What is IPAB? And why do we care?